Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 12  •  04:00PM ET
1.17
Dollar change
+0.02
Percentage change
1.74
%
Index- P/E- EPS (ttm)-2.77 Insider Own28.92% Shs Outstand22.39M Perf Week2.63%
Market Cap26.19M Forward P/E- EPS next Y-2.10 Insider Trans0.00% Shs Float15.91M Perf Month-4.88%
Enterprise Value-41.62M PEG- EPS next Q-0.52 Inst Own39.99% Short Float0.35% Perf Quarter1.74%
Income-61.76M P/S- EPS this Y35.84% Inst Trans1.62% Short Ratio0.35 Perf Half Y11.43%
Sales0.00M P/B0.24 EPS next Y14.84% ROA-35.93% Short Interest0.06M Perf YTD-59.66%
Book/sh4.92 P/C0.22 EPS next 5Y35.63% ROE-44.88% 52W High3.45 -66.09% Perf Year-62.26%
Cash/sh5.25 P/FCF- EPS past 3/5Y-50.29% - ROIC-39.37% 52W Low1.00 17.00% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility4.95% 6.39% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-0.50% Oper. Margin- ATR (14)0.07 Perf 10Y-
Dividend Ex-Date- Quick Ratio10.14 Sales Y/Y TTM- Profit Margin- RSI (14)49.19 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio10.14 EPS Q/Q16.42% SMA202.63% Beta-0.12 Target Price3.00
Payout- Debt/Eq0.45 Sales Q/Q- SMA50-6.88% Rel Volume0.29 Prev Close1.15
Employees64 LT Debt/Eq0.42 EarningsNov 05 BMO SMA200-9.21% Avg Volume157.29K Price1.17
IPOMar 28, 2024 Option/ShortNo / Yes EPS/Sales Surpr.-6.44% - Trades Volume45,900 Change1.74%
Date Action Analyst Rating Change Price Target Change
Jun-02-25Initiated H.C. Wainwright Buy $5
May-28-25Downgrade Leerink Partners Outperform → Market Perform $3
Dec-13-24Downgrade Guggenheim Buy → Neutral
Apr-22-24Initiated Piper Sandler Overweight $20
Apr-22-24Initiated Leerink Partners Outperform $25
Apr-22-24Initiated Guggenheim Buy $24
Nov-24-25 07:00AM
Nov-05-25 07:00AM
Oct-13-25 04:05PM
Aug-05-25 07:00AM
Jun-05-25 04:58PM
04:01PM Loading…
May-23-25 04:01PM
May-14-25 12:00PM
May-09-25 07:00AM
May-01-25 08:23AM
Apr-03-25 07:00AM
Mar-27-25 07:00AM
Feb-26-25 07:00AM
Feb-03-25 10:00AM
Dec-12-24 04:01PM
Nov-25-24 07:00AM
04:01PM Loading…
Nov-07-24 04:01PM
Nov-05-24 07:00AM
Oct-14-24 08:00AM
Sep-11-24 07:00AM
Aug-13-24 04:28AM
03:32AM
Aug-12-24 10:53PM
04:01PM
Jun-05-24 07:00AM
May-13-24 02:53PM
07:00AM
May-06-24 08:00AM
May-01-24 10:05AM
Apr-14-24 11:37AM
Apr-11-24 08:00AM
08:00AM Loading…
Apr-08-24 08:00AM
Mar-27-24 06:55PM
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.